Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-10-20

    Virtual Booth

    An Enquiry

    Menu

    Hypericin

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Soligenix Refreshes US Medical Advisory Board For Lymphoma
    Soligenix Refreshes US Medical Advisory Board For Lymphoma

    14 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/soligenix-updates-united-states-medical-advisory-board-for-cutaneous-t-cell-lymphoma-302582841.html

    PR NEWSWIRE
    14 Oct 2025
    Share Share
    Soligenix Reaches Safety Milestone In Phase 3 Trial Of Hybryte™
    Soligenix Reaches Safety Milestone In Phase 3 Trial Of Hybryte™

    07 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/soligenix-achieves-important-safety-milestone-in-its-confirmatory-phase-3-clinical-trial-of-hybryte-for-the-treatment-of-cutaneous-t-cell-lymphoma-302576600.html

    PR NEWSWIRE
    07 Oct 2025
    Share Share
    Soligenix Manufactures Synthetic Hypericin at Sterling Pharma
    Soligenix Manufactures Synthetic Hypericin at Sterling Pharma

    01 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/soligenix-announces-synthetic-hypericin-successfully-manufactured-at-sterling-pharma-solutions-302495267.html

    PR NEWSWIRE
    01 Jul 2025
    Share Share
    HyBryte™ Clinical Results Show Continued Post-Treatment Improvement
    HyBryte™ Clinical Results Show Continued Post-Treatment Improvement

    02 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hybryte-clinical-results-demonstrate-continued-improvement-post-treatment-302317457.html

    PR NEWSWIRE
    02 Dec 2024
    Share Share
    Expanded HyBryte Shows Positive Results In Early-Stage Lymphoma
    Expanded HyBryte Shows Positive Results In Early-Stage Lymphoma

    09 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/expanded-hybryte-treatment-demonstrating-positive-outcomes-in-early-stage-cutaneous-t-cell-lymphoma-302190262.html

    PR NEWSWIRE
    09 Jul 2024
    Share Share
    Soligenix stock sinks as FDA refuses lymphoma application
    Soligenix stock sinks as FDA refuses lymphoma application

    15 Feb 2023

    // James Waldron FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/soligenxs-stock-sinks-36-after-fda-refuses-consider-lymphoma-therapy-application

    James Waldron FIERCE BIOTECH
    15 Feb 2023
    Share Share